Diosmin

Alternative Medicine Review

Volumn 9, Issue 3, 2004, Pages 308-311

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DIOSMETIN; DIOSMIN; HESPERIDIN; METRONIDAZOLE; NATURAL PRODUCT;

BIOCHEMISTRY; CANCER; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INTERACTION; DRUG MECHANISM; DRUG NUTRIENT INTERACTION; DRUG STRUCTURE; DRUG TRANSFORMATION; HEMORRHOID; HUMAN; LYMPHEDEMA; NONHUMAN; NUTRIENT; PHYTOTHERAPY; PLANT PRODUCT; REVIEW; SCROPHULARIACEAE; SIDE EFFECT; VARICOSIS;

EID: 4644317941     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Cova D, De Angelis L, Giavarini F, et al. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1992;30:29-33.
2. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;63:71-100.
3. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology 2001;52:S49-S56.
4. Smith PD. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 1999;36:24-36.
5. Bergan JJ, Schmid-Schonbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology 2001;52:S43-S47.
6. Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 1997;17:27-33.
7. Labrid C. Pharmacologic properties of Daflon 500 mg. Angiology 1994;45:524-530.
8. Ramelet AA. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema. Angiology 2000;51:19-23.
9. Manthey JA. Biological properties of flavonoids pertaining to inflammation. Microcirculation 2000;7:S29-S34.
10. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized flavonoids. Angiology 2002;53:245-256.
11. Glinski W, Chodynicka B, Roszkiewicz J, et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicenter, controlled, randomized study. Phlebology 1999;14:151-157.
12. Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45:574-578.
13. Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997;57:145-151.
14. Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 1994;45:579-584.
15. Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997;48:93-98.
16. Pecking AP. Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema. Int Angiology 1995;14:39-43.
17. Casley-Smith JR, Casley-Smith JR. The effects of diosmin (a benzo-pyrone) upon some high-protein oedemas: lung contusion, and burn and lymphoedema of rat legs. Agents Actions 1985;17:14-20.
18. Manuel Y, Keenoy B, Vertommen J, De Leeuw I. The effect of flavonoid treatment on the glycation and antioxidant status in type 1 diabetic patients. Diabetes Nutr Metab 1999;12:256-263.
19. Lacombe C, Bucherer C, Lelievre JC. Hemorheological improvement after Daflon 500 mg treatment in diabetes. Int Angiol 1988;7:21-24.
20. Lacombe C, Lelievre JC, Bucherer C, Grimaldi A. Activity of Daflon 500 mg on the hemorheological disorders in diabetes. Int Angiol 1989;8:45-48.
21. Valensi PE, Behar A, de Champvallins MM, et al. Effects of a purified micronized flavonoid fraction on capillary filtration in diabetic patients. Diabet Med 1996;13:882-888.
22. Kuntz S, Wenzel U, Daniel H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr 1999;38:133-142.
23. Yang M, Tanaka T, Hirose Y, et al. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int J Cancer 1997;73:19-24.
24. Tanaka T, Makita H, Kawabata K, et al. Modulation of N-methyl-N- amylnitrosamine-induced rat oesophageal tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in combination. Carcinogenesis 1997;18:761-769.
25. Tanaka T, Makita H, Kawabata K, et al. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 1997;18:957-965.
26. Tanaka T, Makita H, Ohnishi M, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res 1997;57:246-252.
27. Hasanoglu A, Ara C, Ozen S, et al. Efficacy of micronized flavonoid fraction in healing of clean and infected wounds. Int J Angiol 2001;10:41-44.
28. Serfaty D, Magneron AC. Premenstrual syndrome in France: epidemiology and therapeutic effectiveness of 1000 mg of micronized purified flavonoid fraction in 1,473 gynecological patients. Contracept Fertil Sex 1997;25:85-90. [Article in French]
29. Meggiorini ML, Cascialli GL, Luciani S, et al. Randomized study of the use of synthetic diosmin in premenstrual and vascular dysplastic mastodynia. Minerva Ginecol 1990;42:421-425. [Article in Italian]
30. Ciardetti P, Zucconi G, Ottanelli S, Casparis D. Treatment of mastodynia with synthetic diosmin. Ann Ostet Ginecol Med Perinat 1985;106:258-266. [Article in Italian]
31. Bae EA, Han MJ, Lee M, Kim DH. In vitro inhibitory effect of some flavonoids on rotavirus infectivity. Biol Pharm Bull 2000;23:1122-1124.
32. Crespo ME, Galvez J, Cruz T, et al. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med 1999;65:651-653.
33. Rajnarayana K, Reddy MS, Krishna DR. Diosmin pretreatment affects bioavailability of metronidazole. Eur J Clin Pharmacol 2003;58:803-807.